We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.
SametJH, BotticelliM, BharelM. Methadone in primary care – one small step for Congress, one giant leap for addiction treatment. N Engl J Med. 2018;379(1):7–8.
2.
FiscellaK, WakemanSE, BeletskyL. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2019;76(3):229–230.
DavisCS, CarrDH. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. Int J Drug Policy. 2019;73:42–48.
5.
Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine.Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic. Washington, D.C.: National Academies Press; 2020.
PougetER, SandovalM, NikolopoulosGK, FriedmanSR. 2015. Immediate impact of Hurricane Sandy on people who inject drugs in New York City. Subst Use Misuse. 2015; 50(7):878–884.
8.
McClureB, MendozaS, DuncanL, RotrosenJ, HansenH. Effects of regulation on methadone and buprenorphine provision in the wake of Hurricane Sandy. J Urban Health. 2014;91(5):999–1008.
9.
RutkowL, VernickJS, MojtabaiR, RodmanSO, KaufmannCN. Legal challenges for substance abuse treatment during disasters. PS. 2012;63(1):1–9.
ComptonWM, JonesCM, SteinJB, WargoEM. Promising roles for pharmacists in addressing the US opioid crisis. Res Social Adm Pharm. 2019;15(8):910–916.
15.
CalcaterraSL, BachP, ChadiA, . Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–1042.
16.
StrangJ, HallW, HickmanM, BirdSM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993–2008): analyses using OD4 index in England and Scotland. BMJ. 2010;341(2):c4851–c4851.
FrankJW, WakemanSE, GordonAJ. No end to the crisis without an end to the waiver. Sub Abuse. 2018;39(3):263–265.
19.
TierneyM, FinnellDS, NaegleMA, LaBelleC, GordonAJ. Advanced practice nurses: increasing access to opioid treatment by expanding the pool of qualified buprenorphine prescribers. Sub Abuse. 2015;36(4):389–392.
20.
NaegleM, MitchellAM, FlinterM, DunphyL, VanhookP, DelaneyKR. Opioid misuse epidemic: addressing opioid prescribing and organization initiatives for holistic, safe and compassionate care. Nurs Outlook. 2017;65(4):477–479.
21.
BarnettML, LeeD, FrankRG. In Rural Areas, Buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants. Health Aff. 2019;38(12):2048–2056.
22.
WalshSL, LongKQ. Deploying science to change hearts and minds: Responding to the opioid crisis. Prev Med. 2019;128:105780.
